文献速递泌尿男性生殖肿瘤

挽救性转移灶导向治疗对比选择性淋巴结放疗治疗寡复发淋巴结转移性前列腺癌(PEACE V-STORM):一项2期、开放标签、随机对照试验

Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.
PubMed 文献 · Lancet Oncol · 2025-05-05

PEACE V-STORM是一项2期开放标签随机对照试验,在6个国家21家医院纳入196例PET检测到的盆腔淋巴结寡复发(≤5个)前列腺癌患者,1:1随机接受转移灶导向治疗(MDT)或选择性淋巴结放疗(ENRT)。中位随访50个月,4年无转移生存率MDT组63% vs ENRT组76%(HR 0.62,80%CI 0.44-0.86;p=0.063)。ENRT组3级不良事件以尿失禁(6% vs 10%)和腹泻(1% vs 2%)常见,无治疗相关死亡。

要点

  • 4年无转移生存率MDT组63% vs ENRT组76%(HR 0.62,80%CI 0.44-0.86;p=0.063)。
  • ENRT组3级尿失禁9例(10%)vs MDT组6例(6%);腹泻2例(2%)vs 1例(1%)。
  • 未发生治疗相关死亡。

核心结论

  • ENRT较MDT改善无转移生存,本试验将ENRT确立为一种潜在标准治疗策略,但尚待3期试验证实。

研究设计与样本

  • 2期、开放标签、随机对照试验,在澳大利亚、比利时、意大利、挪威、西班牙和瑞士的21家医院开展。
  • 纳入≥18岁、WHO体力状态0-1、组织学确诊前列腺腺癌、根治性局部治疗后PET检测到盆腔淋巴结寡复发(≤5个)的患者。
  • 196例患者随机分配至MDT组(n=99)或ENRT组(n=97),可评估190例(MDT组97例,ENRT组93例);所有患者均为男性;中位随访50个月(IQR 42-58)。
  • MDT组接受挽救性淋巴结清扫或立体定向体部放疗(30 Gy分3次,隔日一次),联合6个月雄激素剥夺治疗。
  • ENRT组接受盆腔45 Gy分25次照射,PET阳性淋巴结同期整合加量至65 Gy,或接受挽救性淋巴结清扫,联合6个月雄激素剥夺治疗。

主要发现

  • 4年无转移生存率MDT组63%(80%CI 56-69)vs ENRT组76%(69-81),HR 0.62(80%CI 0.44-0.86;p=0.063)。
  • 最常见3级不良事件为尿失禁,MDT组6例(6%)vs ENRT组9例(10%);腹泻MDT组1例(1%)vs ENRT组2例(2%)。
  • 未发生治疗相关死亡。

关键数值与推荐

  • 主要终点为无转移生存期,定义为随机化至PET成像出现转移复发(任何M1)或任何原因死亡的时间,按改良意向治疗分析。
  • 4年无转移生存率MDT组63%(80%CI 56-69)vs ENRT组76%(69-81),HR 0.62(80%CI 0.44-0.86;p=0.063)。

临床怎么用

  • 作者认为,本试验通过显示ENRT改善无转移生存,将ENRT确立为一种潜在标准治疗策略,尚待3期试验证实。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Various locoregional treatments exist for PET-CT-detected pelvic nodal oligorecurrences in patients with prostate cancer. We aimed to assess whether elective nodal radiotherapy (ENRT) to the pelvis would be superior to metastasis-directed therapy (MDT). METHODS: PEACE V-STORM is a phase 2, open-label, randomised, controlled trial conducted in 21 hospitals in Australia, Belgium, Italy, Norway, Spain, and Switzerland. Eligible participants were aged 18 years or older, with WHO performance status 0-1 and a histologically confirmed initial diagnosis of adenocarcinoma of the prostate, with a PET-detected pelvic nodal oligorecurrence (up to five nodes) following radical local treatment. Patients were randomly assigned (1:1) to MDT or ENRT. Randomisation was done online by minimisation with randomisation factor 0·80 and was stratified by type of PET tracer (choline vs prostate-specific membrane antigen) and type of MDT used (salvage lymph node dissection vs stereotactic body radiotherapy or simultaneous integrated boost). Participants and researchers were not masked to treatment assignment. Patients in the MDT group had salvage lymph node dissection or stereotactic body radiotherapy (30 Gy in three fractions every other day), with 6 months of androgen deprivation therapy. Patients in the ENRT group received a 45 Gy dose in 25 fractions to the pelvis with a simultaneous integrated boost of 65 Gy to the PET-positive nodes or salvage lymph node dissection, with 6 months of androgen deprivation therapy. The primary endpoint was metastasis-free survival, defined as the time between randomisation and the appearance of a metastatic recurrence (any M1) on PET imaging or death due to any cause, and was analysed per modified intention to treat. This study is registered with ClinicalTrials.gov, NCT03569241, and the Swiss National Clinical Trials Portal, SNCTP000002947, and is active, not recruiting. FINDINGS: Between June 11, 2018, and April 30, 2021, 198 patients were screened for eligibility, 196 of whom were randomly assigned to MDT (n=99) or ENRT (n=97), with 190 evaluable patients (MDT n=97 and ENRT n=93). All patients were male. Data on race and ethnicity were not collected. Median follow-up was 50 months (IQR 42-58). 4-year metastasis-free survival was 63% (80% CI 56-69) in the MDT group and 76% (69-81) in the ENRT group (HR 0·62 [80% CI 0·44-0·86]; p=0·063). The most common grade 3 adverse events were urinary incontinence (six [6%] of 97 in the MDT group vs nine [10%] in the ENRT group) and diarrhoea (one [1%] in the MDT group vs two [2%] in the ENRT group). No treatment-related deaths occurred. INTERPRETATION: To our knowledge, this is the first randomised trial for metachronous PET-detected nodal recurrences comparing two local treatment approaches (MDT and ENRT) in combination with 6 months of androgen deprivation therapy. By showing an improved metastasis-free survival with ENRT, this trial establishes ENRT as a potential standard treatment approach, awaiting a phase 3 trial confirming these results. FUNDING: Movember Foundation, Kom Op Tegen Kanker, Stichting tegen Kanker.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Ost P, Siva S, Brabrand S, et al. Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. 2025. PMID: 40339593. doi:10.1016/S1470-2045(25)00197-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。